A Type 2 diabetes diagnosis in someone’s mid-30s often comes with a mismatch: no excess weight, an active lifestyle, no family history of diabetes, yet a fasting glucose test high enough to warrant the label. It gets treated as Type 2 anyway, since that’s statistically the most likely explanation at that age, and a metformin prescription follows.
For a while, that’s often enough. Blood sugar comes down, A1C improves, and the diagnosis mostly fades into the background. Then, without any change in diet or routine, fasting numbers start climbing again. A dose increase brings them back down, temporarily. A few months later, the same thing happens again.
The appointment where things shift
By the second or third dose increase, a doctor paying close attention will sometimes pause and ask a question that hadn’t come up before: has anyone tested for antibodies? If not, a GAD65 panel alongside a C-peptide test is a reasonable next step, often ordered mostly to rule something out.
It doesn’t always rule something out. A GAD65 result well above the lab’s threshold, combined with a C-peptide reading on the low end of normal and trending downward compared to an earlier baseline, tells a different story than routine Type 2 diabetes.
What the positive result actually means
A positive GAD65 result means the immune system has likely been slowly attacking insulin-producing cells for a while before any diagnosis was made. Metformin can work at first because there’s still enough of the body’s own insulin production for it to be effective. As that production declines, the medication has less and less to work with.
This isn’t Type 2 diabetes. It’s LADA, Type 1 diabetes’ slower, adult-onset cousin that gets mistaken for Type 2 constantly, because on a first glucose test, the two conditions look identical.
What this changes in practice
For someone in this position, an earlier-than-expected move to insulin is common, but it usually comes with a much clearer picture of why, and a treatment plan built around the right numbers instead of the wrong ones. If a Type 2 treatment plan stops working faster than it’s supposed to, that’s worth a direct conversation, not just a dose increase: ask specifically about a GAD65 antibody test and a C-peptide test. Both are standard blood draws that don’t require a specialist referral to order.
For what the test measures and how to read a result, see GAD65 Antibodies Explained.